PBM Vertical Integration Controls Pricing, Pharmacy, and Insurance

The three largest PBMs are each part of a vertically integrated healthcare conglomerate. CVS Health owns CVS Caremark (PBM), CVS Pharmacy (retail), CVS Specialty (specialty pharmacy), and Aetna (insurance). Cigna owns Express Scripts (PBM) and Evernorth (health services). UnitedHealth Group owns OptumRx (PBM), Optum (healthcare services), and UnitedHealthcare (insurance). These three entities process approximately 80% of all U.S. prescriptions. The same corporation decides which drugs are covered, sets the price the insurer pays, determines which pharmacy fills the prescription, and collects premiums from the patient. This matters because there is no independent check on pricing at any point in the transaction. When CVS Caremark negotiates a drug price, it is negotiating with itself across multiple subsidiaries. The "negotiated discount" the PBM reports to the plan sponsor is whatever internal transfer price the conglomerate chooses to set. A self-insured employer hiring CVS Caremark to manage its pharmacy benefit has no way to verify whether the pricing reflects genuine market negotiation or internal profit allocation. The patient is trapped inside the vertical stack. Their employer chose UnitedHealthcare for insurance. UnitedHealthcare requires OptumRx as the PBM. OptumRx mandates mail-order through Optum's pharmacy for maintenance medications. The patient never chose any of these entities and cannot opt out of any layer without leaving their employer's health plan entirely. Competition does not discipline any layer because the patient has no ability to switch. Vertical integration has accelerated because each acquisition passed antitrust review under narrow market definitions. The CVS-Aetna merger was approved in 2018 with minimal conditions. The Cigna-Express Scripts merger was approved the same year. Regulators evaluated each merger in isolation rather than considering the cumulative market power of having three conglomerates control insurance, PBM, and pharmacy functions simultaneously. The FTC's 2024 PBM investigation acknowledged that vertical integration creates conflicts of interest but stopped short of recommending structural remedies. The root cause is that U.S. antitrust enforcement evaluates vertical mergers primarily on short-term consumer price effects, not on structural conflicts of interest or long-term market power accumulation. Each individual merger appeared to offer "efficiencies" that would theoretically lower costs. In practice, total U.S. drug spending has increased every year since these mergers were approved, rising from $335B in 2018 to over $400B in 2023. The efficiencies flowed to the conglomerates as profit, not to patients or plan sponsors as savings.